Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | CCR8 | P51685 | 3/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469801 | 1.00 | KMT2A (0.57) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL3529089 | 0.90 | EDNRA (0.53) | KMT2ARXFP1EDNRAALDH1A1KDM4E | |
| SCHEMBL15461560 | 0.85 | KMT2A (0.59) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL1857055 | 0.85 | KMT2A (0.59) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| Hydrochloric Acid SCHEMBL8861874 | 0.84 | KMT2A (0.57) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL4115318 | 0.84 | KMT2A (0.57) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL4115316 | 0.83 | KMT2A (0.56) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL31689448 | 0.83 | KMT2A (0.56) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL2371826 | 0.81 | KMT2A (0.58) | KMT2ARXFP1CCR8EDNRAALDH1A1 | |
| SCHEMBL1338666 | 0.81 | CCR8 (0.68) | CCR8HPGDEPHX1MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10945963-B2 | Photosensitive capsules and cosmetic and pharmaceutical use thereof | L'OREAL (FR) | 2021-03-16 | — | — | US | disclosed |
| EP-3086754-B1 | PHOTOSENSITIVE CAPSULES AND COSMETIC AND PHARMACEUTICAL USE THEREOF | OREAL (FR) | 2020-12-09 | — | — | EP | disclosed |
| US-5602237-A | FOR DYEING LEATHER OR PELTS IN COLORFAST BROWN SHADES | SANDOZ LTD. (CH) | 1997-02-11 | — | — | US | disclosed |
| US-5378715-A | Sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| EP-0054513-B1 | PROCESS FOR THE PRODUCTION OF PHOTOGRAPHIC COLOUR IMAGES ACCORDING TO THE SILVER DYE BLEACHING PROCESS, AND PHOTOGRAPHIC MATERIAL USED IN THIS PROCESS | CIBA-GEIGY AG (CH) | 1985-10-30 | — | — | EP | disclosed |
| US-4465763-A | OIL SOLUBLE TRIAZINE COMPOUND AND A PHENYL AMINE COUPLER | CIBA GEIGY AG (CH) | 1984-08-14 | — | — | US | disclosed |
| US-4404273-A | Process for the production of photographic color images by the silver dye bleach process | CIBA-GEIGY AG (CH) | 1983-09-13 | — | — | US | disclosed |
| EP-0054513-A1 | Process for the production of photographic colour images according to the silver dye bleaching process, and photographic material used in this process | CIBA-GEIGY AG (CH) | 1982-06-23 | — | — | EP | disclosed |
| US-4169203-A | Water-soluble polymeric colorants containing anionic water-solubilizing groups | DYNAPOL (US) | 1979-09-25 | — | — | US | disclosed |
| US-4167422-A | Laked high molecular weight dyes | DYNAPOL (US) | 1979-09-11 | — | — | US | disclosed |
| US-4000118-A | COLORINGS | DYNAPOL SHAREHOLDERS' LIQUIDATING TRUST THE | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | KMT2A 3540/4885RXFP1 1805/4885CCR8 2227/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | KMT2A 2351/4885RXFP1 4676/4885CCR8 4669/4885 |
| US-10945963-B2 | Photosensitive capsules and cosmetic and pharmaceutical use thereof | KRT18, CEP170, DSG1 | KMT2A 397/4885RXFP1 4749/4885CCR8 4867/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | KMT2A 23/4885RXFP1 3249/4885CCR8 4651/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | KMT2A 3540/4885RXFP1 1805/4885CCR8 2227/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | KMT2A 3540/4885RXFP1 1805/4885CCR8 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.